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Introduction: The aim of this study was to describe the character-
istics and epidermal growth factor receptor (EGFR) mutational
status of patients with non-small cell lung cancer (NSCLC) with
osteoblastic reactions diagnosed before or during treatment with
EGFR tyrosine kinase inhibitors (TKIs).
Methods: Retrospective study including patients with 36 NSCLC
with at least one site of osteoblastic reaction at the time of diagnosis
or during treatment with EGFR-TKI.
Results: The rate of patients with mutated EGFR tumors with
osteoblastic reactions before or after EGFR-TKI treatment was
similar. Median progression-free survival (PFS) for the entire group
was more than 9 months and median survival was more than 12
months. There was no statistically significant difference in survival
between patients with osteoblastic reactions before initiation of TKI
and those diagnosed during TKI treatment. Patients with extraosse-
ous metastases when treated with TKI had the lowest survival (P 
0.0001).
Conclusions: In patients with NSCLC treated with TKI, initial or
development of an osteoblastic reaction seems to be related to a
more favorable outcome. In patients with osteoblastic reactions,
tumors present with clinical and biologic characteristics of better
survival and response to TKI. The occurrence of osteoblastic reac-
tions during treatment with TKI, while primary tumor and metasta-
ses are stable or in response, should not be considered as disease
progression.
Key Words: EGFR mutations, Bone metastasis, Lung cancer,
Tyrosine kinase inhibitors, Osteoblastic reaction.
(J Thorac Oncol. 2010;5: 491–496)
Bone metastases are a frequent complication of non-smallcell lung cancer (NSCLC), occurring in up to 30 to 40%
of patients during the progression of NSCLC. They have been
characterized as osteolytic or osteoblastic. This classification
actually represents two extremes of a continuum in which
deregulation of the normal bone remodeling process occurs
and patients can have both osteolytic and osteoblastic metas-
tasis or mixed lesions. Generally in NSCLC, metastases are
osteolytic, and there have only been very rare reports of
osteoblastic reactions during chemotherapy for lung cancers,
particularly in small cell carcinomas.1,2
A phenomenon, called osteoblastic flare, is a temporary
increase in tracer uptake associated with therapy response of
bone metastases that were previously undetected and is a
healing response to effective cytostatic chemotherapy. It has
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also been widely documented in breast and prostate cancer,
but only very rarely in NSCLC.3 The osteoblastic reaction is
the radiographic equivalent of osteoblastic flare and is defined
as the appearance of new osteoblastic bone lesions while
disease response is observed at other tumor sites. It has also
been described in breast and prostate cancer.4,5 Indeed, a
retrospective study in 24 patients with newly diagnosed small
cell lung cancer and bone metastases indicated that osteoblas-
tic reaction as a healing reaction seems to occur in most
patients with small cell lung cancer and bone metastases and
therefore should not be misinterpreted as progressive dis-
ease.2 Detection of new osteoblastic bone metastases must be
differentiated from a healing reaction due to response to
chemotherapy, radiation therapy, or alternatively to effects
related to drugs, e.g biphosphonates.
Molecular targeted therapies, such as the epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) are widely used in the treatment of metastatic
NSCLC. They provide a different mechanism of action from
chemotherapy and can be much more specific in their ap-
proach to cancer treatment by identifying subsets of patients
who will derive the most benefit. Erlotinib and gefitinib are
reversible TKIs of EGFR (EGFR-TKIs) that have demon-
strated efficacy in the second- and third-line treatment of
metastatic NSCLC6 compared with placebo and are therapeu-
tically equivalent to docetaxel with better clinical safety.7,8 It
has been observed that never smokers or former smokers,
Asians and, to a lesser extent, women, as well as patients with
adenocarcinoma are more likely to respond to EGFR-TKI
treatment.9–11 These clinical characteristics are highly asso-
ciated with the presence of amplified and/or mutated exons 18
through 21 of the EGFR gene, making the tumor cells
extremely sensitive to EGFR-TKI.12–14
It also appears that certain types of metastases respond
particularly well to EGFR-TKI, particularly in the case of
carcinomatous meningitis.15 It has recently been suggested
that the presence of an osteoblastic reaction is also associated
with a significant response to EGFR-TKI16 and that bone
condensation may increase or even appear within osteolytic
lesions over time (Figure 1A, B). In these observations, the
osteoblastic reactions were either present before receiving
TKI and increased during treatment or appeared during treat-
ment in areas considered to be free of metastases.
The mechanism of the onset of this osteoblastic reac-
tion is not fully understood; the action of the TKI can be
considered as either having a direct therapeutic effect on the
metastasis for which progression is thus impeded or stopped17
or as having an effect on the osteoblasts and osteoblasts.18
The prognostic significance of these bone condensations
needs defining and, in particular, the significance of an
osteoblastic reaction appearing during treatment in bone seg-
ments considered free of metastases.
The purpose of this retrospective study was to describe
the characteristics of patients who presented an osteoblastic
reaction, at the time of NSCLC diagnosis or during treatment
with EGFR-TKI. We also intended to investigate the tumor
EGFR mutational status, the progression of the original
tumor, bone metastases, and any other metastases, during the
course of the EGFR-TKI treatment.
MATERIALS AND METHODS
This retrospective study included 36 patients with his-
tologically/cytologically proven NSCLC and presenting at
least one site of osteoblastic reaction at the time of diagnosis,
at the start of, or during treatment with an EGFR-TKI
(erlotinib or gefitinib). The EGFR-TKI treatment had to have
been evaluated at least once by medical imaging (computed
tomography, bone scintigraphy, and magnetic resonance im-
aging) and followed-up until death or until the assessment
date of August 1, 2008.
All files were reviewed by the same investigator (E.P.),
and the information was collected on a standardized collec-
tion sheet. Clinical characteristics included age, gender, eth-
nicity, smoking history (nonsmoker  less than 100 ciga-
rettes in their lifetime; former smoker  no smoking for over
a year; and smoker), histologic type, tumor, node, metastasis
stage at initial diagnosis, number and type of metastasis at
FIGURE 1. A, Osteoblastic response of a lumbar vertebra
diagnosed before treatment. B, Pelvic osteoblastic response
diagnosed during treatment with TKI.
Pluquet et al. Journal of Thoracic Oncology • Volume 5, Number 4, April 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer492
initiation of EGFR-TKI, type of bone metastasis (single or
multiple, condensing bone, or mixed). Osteoblastic reactions
were grouped according to the time of diagnosis (known
before treatment with TKI or appearing during treatment with
TKI). Therapeutic characteristics included number of lines of
treatment, type of TKI, cutaneous tolerance, administration of
bisphosphonates before or after initiation of TKI. Tumor
evolution with treatment based on best response evaluated
according to RECIST criteria,19 time to progression and date
of death. On available tissues, tests for EGFR mutations
(exons 19 and 21) and K-ras were performed using DNA
sequencing in four centers (Strasbourg, Grenoble, Caen,
Paris), that had harmonized their analysis methods by apply-
ing a quality assurance procedure.
Statistical Analyses
Analyses comparing categorical variables were carried
out using Fisher exact test tests. Analyses comparing contin-
uous variables were carried out using t tests. Survival was
calculated from the date of the first dose of TKI until
progression (for PFS) or death (for overall survival); event-
free individuals were censored. Survival of the different
groups was compared using the log-rank test.
Multivariate analysis using the Cox model assessed the
impact of the following variables on overall survival: smok-
ing habit, gender, histology and the presence or increase/
onset of an osteoblastic reaction in patients for whom ex-
traosseous tumor metastases were responding or stable.
RESULTS
The clinical, therapeutic, and biologic characteristics of
the 36 patients included in this retrospective study are pre-
sented in Table 1. Twenty-one (58.3%) patients were women
and 32 (88.9%) had an adenocarcinoma. The other histologic
subtypes were large-cell carcinoma (two patients), squamous
cell carcinoma, and pleomorphic carcinoma (one patient
each). Thirty-one patients were treated with erlotinib and five
patients with gefitinib (Table 1). Four patients received a
first-line treatment when participating in a clinical, 13 re-
ceived a second-line treatment, and the 16 others a third-line
treatment or beyond.
Thirteen patients were treated with bisphosphonates be-
fore the initiation of TKI. Calcemia before initiation of treatment
was known in 22 patients with a median value of 2.32 micro-
moles (range 2.04–2.60); no patients had hypercalcemia.
Biopsies embedded in paraffin were available for 30
patients (Table 1). Testing for mutations showed that 13 of 25
patients (54%) presented with an EGFR mutation including
exon 19 (9 of 25 patients), exon 21 (4 of 24 patients), and
K-ras mutation (1 of 23 patient). The proportion of patients
with an EGFR mutation was similar in patients presenting
with condensing bone lesions before or after initiation of
EGFR-TKI.
On the basis of the RECIST criteria, 14 (38.9%) pa-
tients were assessed as responders or stable to treatment with
TKI and 22 (61.1%) patients in progression. However, among
these 22 patients, only five had a well-documented pro-
gression other than bone metastases (lung and liver, three
patients each and one patient had a nodular metastasis). In
the 17 other patients, the progression involved onset of an
osteoblastic reaction in 11 patients and an increase in
number or spreading of already known osteoblastic reac-
tions in six patients.
The median treatment duration was 287 days (range
48–1092) for all patients. There was no difference in the
duration of TKI treatment in patients with osteoblastic reac-
tions before treatment start and those with osteoblastic reac-
tions detected during treatment. Treatment was still in
progress in seven patients (19.4%) at the assessment date.
Treatment with TKI was discontinued in 29 patients for the
following reasons: disease progression (26 patients), adverse
events (two patients, grade 4 asthenia and grade 4 respiratory
disease), and death from concomitant disease (one patient).
Median PFS for the entire group was 300 days (9.8
months) Table 2. At the assessment date, nine patients were
alive and 27 were deceased (25 deaths related to the disease
and two due to concomitant disease). With a median fol-
low-up period of 868 days, the median survival of the entire
group was 408 days (13.4 months) with a survival rate at 1
and 2 years of 52 and 26%, respectively. Overall survival and
PFS curves evaluating the impact of the response to TKI with
or without an osteoblastic reaction are presented in Figure 2A,
B. There was no statistically significant difference in PFS or
overall survival between the group of patients presenting with
an osteoblastic reaction before initiation of TKI and those for
whom the osteoblastic reaction appeared during the treatment
with TKI. Patients who presented with progression of ex-
traosseous metastases while treated with TKI had poorer PFS
than patients presenting with an osteoblastic reaction before
initiation of TKI (p  0.0001) or during treatment (p 
0.0001). Also, patients with progression of extraosseous me-
tastases while treated with TKI had poorer overall survival
than patients with an osteoblastic reaction before initiation of
TKI (p  0.009) and during treatment (p  0.009).
Among the other parameters studied in single variable
analysis, previous smoking habit (p  0.0003) and perfor-
mance status (p  0.006) were associated with a better
survival. The other factors including histology, gender, rash,
or EGFR mutations had no impact on survival. Smoking also
had an impact on PFS (p  0.005).
A multivariate analysis using the Cox model is pre-
sented in Table 3. The size of the cohort and the strong
predominance of women patients and adenocarcinoma prob-
ably explain the lack of significance of statistical test that
could not demonstrate an impact of these two parameters on
survival.
DISCUSSION
If RECIST criteria are strictly applied to patients with
new lesions exclusively in the form of osteoblastic reactions,
should the diagnosis be progression and lead to a modifica-
tion of the treatment administered? Indeed, the appearance of
an osteoblastic reaction during an active antitumor treatment
can complicate the definition of best overall response using
RECIST criteria. In this retrospective study, we have ana-
lyzed 36 cases of patients with NSCLC presenting with
osteoblastic reactions either before treatment with TKI or
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during treatment with TKI. The progression of the primary
tumor and its metastases during TKI treatment was studied.
In most patients, osteoblastic reactions were considered as
bone metastases, they were multiple and associated with
extraosseous metastases. Most patients (70%) had not re-
ceived bisphosphonates before initiation of TKI.
In this cohort, we found a vast predominance of non-
smoker or never smoker patients (91.6%), adenocarcinomas
(89%), and finally, women patients were found more fre-
quently than is usually observed in NSCLC (58%). There was
no difference between patients with documented osteoblastic
reaction before or after treatment with TKI (Table 1). EGFR
Mutations were observed in approximately 50% of the pa-
tients with 9 (36%) deletions of exon 19 and 4 (16.7%)
mutations of exon 21; K-ras mutations were observed in 4%
of the patients.
These clinical and biologic characteristics are very
different from those observed in pivotal studies with TKIs. In
TABLE 1. Patients and Disease Characteristics Based on Whether or Not an Osteoblastic Reaction
is Present at the Time of TKI Administration
Osteoblastic Reaction Initially
Present, n  23 (%)
Osteoblastic Reaction During
TKI Treatment, n  13 (%) p
Age (mean, range) 61 (27–80) 60 (36–76) NS
Gender
Males 10 (43.5) 5 (38.5) NS
Females 13 (56.5) 8 (61.5)
Asian origin 0 1 (7.7) NS
Smoker
Active 1 (4.3) 2 (15.4) NS
Former 9 (39.1) 3 (23)
Never 13 (56.5) 8 (61.5)
Stage
IIIA/B 6 (26) 6 (46.1) NS
IV 17 (73.9) 7 (53.8)
Histology
Adenocarcinomas 21 (91.3) 11 (84.6) NS
Other 2 (8.7) 2 (15.4)
Performance status
0 3 (13) 1 (7.7)
1 9 (39.1) 3 (23) NS
2 9 (39.1) 7 (53.8)
3 2 (8.7) 2 (15.4)
Metastasis
Solitary 0 2 (15.4) NS
Multiple 23 (100) 11 (84.6)
Multiple bone 20 (86.9) 6 (46.1)
Mutation
Exon 19 deletion 5 (14 analyses) 4 (11 analyses)
Exon 21 mutation 3 (14 analyses) 1 (10 analyses) NS
K-ras mutations 0 (14 analyses) 1 (10 analyses)
Treatment with Erlotinib 20 (86.9) 11 (84.6) NS
Treatment with Gefitinib 3 (13) 2 (15.4)
Line of treatment
1st 3 (13) 1 (7.7)
2nd 6 (26) 7 (53.8) NS
3rd 13 (56.1) 3 (23)
4th 1 (4.3) 2 (15.4)
Treatment duration (d, mean,
median, range)
381, 267, 48–1017 350, 308, 56–1092 NS
Rash grade 2 10 (43.5) 6 (46.1) NS
Use of bisphosphonates
Before TKI 11 (47.8) 2 (15.4) 0.03
During TKI 7 (30.4) 2 (15.4)
No 11 (47.8) 11* (84.6)
NS, not significant; TKI, tyrosine kinase inhibitor. * P  0.03.
Pluquet et al. Journal of Thoracic Oncology • Volume 5, Number 4, April 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer494
the National Cancer Institute of Canada Clinical Trials
Group, randomized, phase III, BR21 study, assessing 150 mg
daily of single-agent erlotinib in patients with locally ad-
vanced or metastatic NSCLC after failure of at least one
previous chemotherapy regimen, there were 35.5% women,
50.4% adenocarcinomas, and a majority of smokers.7 Simi-
larly, in the INTEREST study, a randomized phase III trial
assessing gefitinib versus docetaxel in previously treated
NSCLC, there were 36.4% women, 56.2% adenocarcinomas,
and 79.8% smokers.8
In study BR21, KRAS was mutated in 15% of the
patients and EGFR was mutated in 18% of the patients,
whereas in the INTEREST study, EGFR mutations were
observed in 14% of patients and K-ras in 17% of the patients.
The response rate is much higher than that usually
observed when bone metastases are not taken into account,7,8
and the median survival for the entire group was greater than
12 months, which is longer than that usually reported with
TKIs (6.7 months in the BR21 study and 8.4 months in the
INTEREST study). The PFS differences are even more
important, because the median was greater than 9 months
in this study compared with 2.2 months in the BR21 and
INTEREST studies.
Patients who presented with progression of extraosse-
ous metastases when treated with TKI had poorer survival
than the others (p  0.0001). There was no statistically
significant difference in survival between patients with os-
teoblastic reactions before initiation of TKI and during the
treatment with TKI. Furthermore, there was no difference in
survival between those who were responders or stable when
treated with TKI and those who presented with an onset of
osteoblastic reaction or for whom osteoblastic reactions in-
creased in size or number. In both univariate and multivariate
analysis, these patients had better survival.
In conclusion, in patients with NSCLC treated with
TKI, the initial presence or development of an osteoblastic
reaction seems to be related to a more favorable outcome
compared with patients with extraosseous metastasis. In pa-
TABLE 2. Response and Survival Characteristics of the Cohort Studied Based on






Treatment (n  13)
PR, SD/progression (excluding bone lesions) 20/3 11/2
PR, SD/progression (including bone lesions) 14/9 0/13
Median progression-free survival 252 d 342 d
Median survival 450 d 350 d
2-yr survival 31% 13.5%
TKI, tyrosine kinase inhibitor; PR, partial response; SD, stable disease.
FIGURE 2. A, Analysis of progression-free survival based on the effect of TKI. A, Response or stable with increase or onset of
osteoblastic reaction (17 patients); B, response or stable with stable osteoblastic reaction (14 patients); C, progression of ex-
traosseous sites (five patients) (overall log rank p  0.0001, A versus B p  0.87, A versus C p  0.0001, B versus C p 
0.0001). B, Analysis of overall survival based on the effect of TKI. A, response or stable with increase or onset of osteoblastic
reaction (17 patients); B, response or stable with stable osteoblastic reaction (14 patients); C, progression of extraosseous sites
(five patients) (overall log rank p, 0.002; A versus B p, 0.2; A versus C p, 0.009; B versus C p, 0.009).
TABLE 3. Analysis Using the Cox Model, Integrating
Standard Prognostic Parameters with the Presence of Stable
or Increased Osteoblastic Reaction in the Absence of
Progression on Extraosseous Metastases
Parameter HRs (95% CI; p Values)
Never or former smoker 0.13 (0.02–0.71; 0.01)
Adenocarcinoma histology 1.5 (0.32–6.8; 0.6)
Female 0.47 (0.2–1.2; 0.12)
Osteoblastic reaction increased 0.29 (0.09–0.89; 0.03)
Stable osteoblastic reaction 0.13 (0.03–0.47; 0.002)
HR, hazard ratio; CI, confidence interval.
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tients with an osteoblastic reaction (before or during treat-
ment), the tumors present with clinical and biologic charac-
teristics of a response to TKI as well as better survival. Thus,
the occurrence of an osteoblastic reaction during treatment
with TKI, although extraosseous metastases are stable or in
response, should not be considered as disease progression.
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